The Residual Risk Reduction Initiative

Your login
Your password
Confirm your password
Your email
I agree to receive the R3i newsletter
Yes No

Prof. Christoph Wanner

University Hospital Würzburg,
Germany


Current position

1994 -	Professor of Medicine, Chief, Division of Nephrology, Dept of Medicine and Scientific director, Clinical Trial Unit, University Hospital of Würzburg Julius-Maximilians-University, Würzburg, Germany

Past position

1991	Assistant Professor and faculty member
1992	Research sebatical at the NIH, NHLBI, Molecular Disease Branch (B. Brewer), USA

Scientific training

1983 - 1989	Residency and internship at the Universities of Zurich, Switzerland and Freiburg, Germany
1990	Habilitation (equivalent to PhD)

Professional Associations

	Steering committee member and central Europe coordinator of SHARP (study of heart and renal protection).

Publicatins (selection)

*R3i related paper:* Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, Ritz E for the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New Engl J Med 2005;353:238-248

*Best cited paper* (710 citations): Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658

Research

Scientific areas of interest are : (1) the role of lipids in the progression of renal and vascular disease (glomerulosclerosis and atherosclerosis in kidney failure patients) (2) elucidation of the inflammatory response syndrome in diabetic nephropathy, chronic kidney disease and kidney failure. 1998-2005 PI of the 4D study, a statin outcome trial in diabetic patients on dialysis